NCT04480957 - Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL

ARCT-021 Dose 1

ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)

BIOLOGICAL

ARCT-021 Dose 2

ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

BIOLOGICAL

ARCT-021 Dose 3

ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

BIOLOGICAL

ARCT-021 Dose 4

ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

BIOLOGICAL

ARCT-021 Dose Regimen 1

ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

BIOLOGICAL

ARCT-021 Dose Regimen 2

ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021

OTHER

Placebo

Sterile 0.9% saline

Trial Locations (1)

169608

SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital, Singapore